CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca today announced that the European Commission (EC) has approved a new indication for Faslodex (fulvestrant) in combination with a CDK4/6 inhibitor, palbociclib, for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer in women who have received prior endocrine therapy.1
David Fredrickson, Executive Vice President, Head of the Oncology Business Unit at AstraZeneca, said: “For many years fulvestrant has been used as an effective monotherapy treatment for women with hormone receptor positive breast cancer. The first EU approval of fulvestrant for use in combination with a CDK4/6 inhibitor reinforces the value of fulvestrant as an endocrine agent of choice for advanced breast cancer patients, building on the EU first-line monotherapy approval earlier this year with FALCON.”
The EU approval is based on data from the Phase III PALOMA-3 trial, which showed a statistically significant increase in investigator-assessed median PFS of 4.9 months (9.5 months vs 4.6 months) in patients who received fulvestrant 500 mg and palbociclib 125 mg over fulvestrant and placebo (HR: 0·46; 95% CI: 0·36–0·59; p<0·0001).2
– ENDS –
NOTES TO EDITORS
About Advanced Breast Cancer
Advanced/metastatic breast
cancer refers to Stage III and IV breast cancer. Stage III disease may
also be referred to as locally-advanced breast cancer, while metastatic
disease is the most-advanced stage of breast cancer (Stage IV), and
occurs when cancer cells have spread beyond the initial tumour site to
other organs of the body outside the breast. Since there is no cure for
the disease, the goal of current treatment is to delay disease worsening
or death. In 2012, there were an estimated 1.67 million new cases
worldwide – one in four of all cancer cases. In Europe the estimated
5-year prevalence of breast cancer in 2012 was 1,814,572 cases.
About PALOMA-3
PALOMA-3 is a Phase III international,
randomised, double-blind, parallel group, multicentre study, sponsored
by Pfizer Inc., of fulvestrant plus palbociclib vs fulvestrant plus
placebo conducted in women with HR+/HER2- advanced or metastatic breast
cancer, regardless of their menopausal status, whose disease progressed
after endocrine therapy. The study evaluated 521 pre/postmenopausal
women who were randomised 2:1 to fulvestrant plus palbociclib or
fulvestrant plus placebo. Women who were either premenopausal
(meaning they had not reached menopause), or perimenopausal (meaning
that their bodies were making the natural transition toward menopause),
were therapeutically induced to become postmenopausal and represented
20.7% of the study population.
Patients enrolled in this study had a median age of 57 years (range 29 to 88). The majority of patients in the study were white (74%). All patients had an ECOG (Eastern Cooperative Oncology Group) PS of 0 or 1, and 80% were postmenopausal. All patients had received prior systemic therapy and 75% of patients had received a previous chemotherapy regimen. Twenty-five percent of patients had received no prior therapy in the metastatic disease setting, 60% had visceral metastases, and 22% had bone only disease.
Fulvestrant 500 mg was given as two 5 ml injections, one in each buttock, on days 1, 15, 29 and once monthly (28 ± 3 days) thereafter. Palbociclib was given orally at a dose of 125 mg daily for 21 consecutive days followed by 7 days off treatment. Patients continued to receive their assigned treatment until objective disease progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent, whichever occurred first.
About Fulvestrant
Fulvestrant is indicated for the
treatment of oestrogen receptor positive, locally advanced or metastatic
breast cancer in postmenopausal women not previously treated with
endocrine therapy, or with disease relapse on or after adjuvant
anti-oestrogen therapy, or disease progression on anti-oestrogen therapy.
In the US, fulvestrant is licensed for use with palbociclib for the treatment of women with HR+, HER2- locally advanced or metastatic breast cancer, whose cancer has progressed after endocrine therapy. In Japan, fulvestrant is also approved for use in combination with any CDK4/6 inhibitor. Fulvestrant represents a hormonal treatment approach that helps to slow tumour growth by blocking and degrading the oestrogen receptor – a key driver of disease progression.
Fulvestrant is approved in over 80 countries as a monotherapy to treat ER+ advanced breast cancer patients. It is currently being evaluated in combination with medicines from various drug classes for the treatment of women with HR+ advanced breast cancer.
About AstraZeneca in Oncology
AstraZeneca has a deep-rooted
heritage in Oncology and offers a quickly-growing portfolio of new
medicines that has the potential to transform patients’ lives and the
Company’s future. With at least six new medicines to be launched between
2014 and 2020, and a broad pipeline of small molecules and biologics in
development, we are committed to advance New Oncology as one of
AstraZeneca’s five Growth Platforms focused on lung, ovarian, breast and
blood cancers. In addition to our core capabilities, we actively pursue
innovative partnerships and investments that accelerate the delivery of
our strategy as illustrated by our investment in Acerta Pharma in
haematology.
By harnessing the power of four scientific platforms – Immuno-Oncology, Tumour Drivers and Resistance, DNA Damage Response and Antibody-Drug Conjugates – and by championing the development of personalised combinations, AstraZeneca has the vision to redefine cancer treatment and one day eliminate cancer as a cause of death.
About AstraZeneca
AstraZeneca is a global, science-led
biopharmaceutical company that focuses on the discovery, development and
commercialisation of prescription medicines, primarily for the treatment
of diseases in three main therapy areas - Oncology, Cardiovascular &
Metabolic Diseases and Respiratory. The Company also is selectively
active in the areas of Autoimmunity, Neuroscience and Infection.
AstraZeneca operates in over 100 countries and its innovative medicines
are used by millions of patients worldwide. For more information, please
visit www.astrazeneca.com
and follow us on Twitter @AstraZeneca.
References
1 European Commission. Pharmaceuticals - Community Register.
Available from: http://ec.europa.eu/health/documents/community-register/html/h269.htm
[Last Accessed November 2017]
2 Cristofanilli M, et al.
Fulvestrant plus palbociclib versus fulvestrant plus placebo for
treatment of hormone-receptor-positive, HER2-negative metastatic breast
cancer that progressed on previous endocrine therapy (PALOMA-3): final
analysis of the multicentre, double-blind, Phase 3 randomised controlled
trial. Lancet Oncol. 2016 Apr;17(4):425-39
